Clinical Trial Update: Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating everolimus with octreotide acetate with or without bevacizumab in locally advanced or metastatic pancreatic neuroendocrine tumors; stud…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Neuroendocrine Tumor

Drugs mentioned

• Bevacizumab (bevacizumab)
• Everolimus (everolimus)
• OCTREOTIDE ACETATE (octreotide acetate)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Pancreatic Neuroendocrine Tumor, Locally Advanced Pancreatic Neuroendocrine Tumor | Phase 2 | Status: COMPLETED | Results posted: 2016-02-11